智通财经网·2026-03-30 15:33Group 1: Financial Performance - In 2025, the company achieved a total revenue of RMB 173.4 billion, with overseas revenue accounting for 54.7% [1] - The four core enterprises—Fosun Pharma, Yuyuan, Fosun Portugal Insurance, and Fosun Tourism—generated total revenue of RMB 128.2 billion, representing a 3 percentage point increase in their contribution to the group's total revenue, reaching 74% [1] - The company's net cash flow from operating activities remained positive, and interest expenses and management costs showed a steady decline [1] Group 2: Debt Management and Financing - The company continues to implement an active and prudent liquidity and debt management policy, focusing on diversifying financing channels and increasing the disposal of non-core assets to solidify cash reserves [2] - In 2025, the company expanded its offshore dollar bond from USD 300 million to USD 500 million and issued a four-year USD 400 million bond and a five-year EUR 400 million bond, extending the debt maturity [2] - As of December 2025, the company's financing cost was 5.0%, a decrease of over 60 basis points compared to the end of 2024 [2] Group 3: Asset Optimization Strategy - Since 2020, the company has prioritized debt reduction as a key financial strategy, achieving an exit from non-strategic and non-core assets worth over RMB 17 billion [3] - The management remains committed to disposing of non-core assets to strengthen cash reserves and continuously reduce liabilities [3]